First Test Meeting

Meeting
Wednesday 14th April 16:00 - 17:00 GMT
Participate now via

Lorem ipsum dolor sit amet consectetur adipisicing elit. Cumque odio consequuntur ut vitae! Iste ducimus voluptatum vitae natus, nisi dolor amet. Quos quisquam alias iure velit nobis deserunt corporis perferendis.

Lorem ipsum dolor sit amet consectetur adipisicing elit. Cumque odio consequuntur ut vitae! Iste ducimus voluptatum vitae natus, nisi dolor amet. Quos quisquam alias iure velit nobis deserunt corporis perferendis.

Wednesday 14th Apr: 16:00 - 17:00 GMT
Online Only Via Zoom

Featuring

  • Example - Speaker

    Example

    Speaker

Downloads

Related Content

Article

Article Example One

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim.

View
Article

Article Example Two

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim.

View
Article

Article Example Three

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim.

View

Are you a healthcare professional?

The information provided on this website is intended for use by healthcare professionals practicing in the Europe. The dissemination of this information may be subject to different medical and regulatory requirements across Europe.​

I confirm that I am a healthcare professional practicing in Europe I am a member of the public

All the content about BRINEURA®▼ (cerliponase alfa) currently available on CLN2 Meetings platform has been approved and is consistent with the latest and most updated version of EU SmPC.

CLN2 Meetings' content is periodically reviewed by BioMarin and may be subject to changes to assure compliance with European general regulations around on promotion of prescription medicines.

You can always find out the most updated version of Brineura's abbreviated prescribing information (API) under the menu option "API" at the top bar navigation.

Close

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.